No evidence for cell activation or brain vaso-occlusion with plerixafor mobilization in sickle cell mice

Erika Choi, Craig A. Branch, Min-Hui Cui, Karina Yazdanbakhsh, Narla Mohandas, Henny H. Billett, Patricia A. Shi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Gene therapy for sickle cell disease is currently in active trials. Collecting hematopoietic progenitor cells safely and effectively is challenging, however, because granulocyte colony stimulating factor, the drug used most commonly for mobilization, can cause life-threatening vaso-occlusion in patients with sickle cell disease, and bone marrow harvest requires general anesthesia and multiple hip bone punctures. Plerixafor is an inhibitor of the CXCR4 chemokine receptor on hematopoietic progenitor cells, blocking its binding to SDF-1 (CXCL12) on bone marrow stroma. In support of a clinical trial in patients with sickle cell disease of plerixafor mobilization (NCT02193191), we administered plerixafor to sickle cell mice and found that it mobilizes hematopoietic progenitor cells without evidence of concomitant cell activation or brain vaso-occlusion.

Original languageEnglish (US)
Pages (from-to)67-70
Number of pages4
JournalBlood Cells, Molecules, and Diseases
Volume57
DOIs
StatePublished - Mar 1 2016

Fingerprint

Sickle Cell Anemia
Hematopoietic Stem Cells
Brain
Bone Marrow
Pelvic Bones
CXCR4 Receptors
Chemokine Receptors
Granulocyte Colony-Stimulating Factor
Punctures
Genetic Therapy
General Anesthesia
Clinical Trials
Pharmaceutical Preparations
JM 3100

Keywords

  • Endothelial cell activation
  • Hematopoietic progenitor cell mobilization
  • Neutrophil activation
  • Platelet activation
  • Plerixafor
  • Sickle cell disease

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Hematology
  • Cell Biology

Cite this

No evidence for cell activation or brain vaso-occlusion with plerixafor mobilization in sickle cell mice. / Choi, Erika; Branch, Craig A.; Cui, Min-Hui; Yazdanbakhsh, Karina; Mohandas, Narla; Billett, Henny H.; Shi, Patricia A.

In: Blood Cells, Molecules, and Diseases, Vol. 57, 01.03.2016, p. 67-70.

Research output: Contribution to journalArticle

@article{0df406eddb9943d8975c0d486808a24f,
title = "No evidence for cell activation or brain vaso-occlusion with plerixafor mobilization in sickle cell mice",
abstract = "Gene therapy for sickle cell disease is currently in active trials. Collecting hematopoietic progenitor cells safely and effectively is challenging, however, because granulocyte colony stimulating factor, the drug used most commonly for mobilization, can cause life-threatening vaso-occlusion in patients with sickle cell disease, and bone marrow harvest requires general anesthesia and multiple hip bone punctures. Plerixafor is an inhibitor of the CXCR4 chemokine receptor on hematopoietic progenitor cells, blocking its binding to SDF-1 (CXCL12) on bone marrow stroma. In support of a clinical trial in patients with sickle cell disease of plerixafor mobilization (NCT02193191), we administered plerixafor to sickle cell mice and found that it mobilizes hematopoietic progenitor cells without evidence of concomitant cell activation or brain vaso-occlusion.",
keywords = "Endothelial cell activation, Hematopoietic progenitor cell mobilization, Neutrophil activation, Platelet activation, Plerixafor, Sickle cell disease",
author = "Erika Choi and Branch, {Craig A.} and Min-Hui Cui and Karina Yazdanbakhsh and Narla Mohandas and Billett, {Henny H.} and Shi, {Patricia A.}",
year = "2016",
month = "3",
day = "1",
doi = "10.1016/j.bcmd.2015.12.008",
language = "English (US)",
volume = "57",
pages = "67--70",
journal = "Blood Cells, Molecules, and Diseases",
issn = "1079-9796",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - No evidence for cell activation or brain vaso-occlusion with plerixafor mobilization in sickle cell mice

AU - Choi, Erika

AU - Branch, Craig A.

AU - Cui, Min-Hui

AU - Yazdanbakhsh, Karina

AU - Mohandas, Narla

AU - Billett, Henny H.

AU - Shi, Patricia A.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Gene therapy for sickle cell disease is currently in active trials. Collecting hematopoietic progenitor cells safely and effectively is challenging, however, because granulocyte colony stimulating factor, the drug used most commonly for mobilization, can cause life-threatening vaso-occlusion in patients with sickle cell disease, and bone marrow harvest requires general anesthesia and multiple hip bone punctures. Plerixafor is an inhibitor of the CXCR4 chemokine receptor on hematopoietic progenitor cells, blocking its binding to SDF-1 (CXCL12) on bone marrow stroma. In support of a clinical trial in patients with sickle cell disease of plerixafor mobilization (NCT02193191), we administered plerixafor to sickle cell mice and found that it mobilizes hematopoietic progenitor cells without evidence of concomitant cell activation or brain vaso-occlusion.

AB - Gene therapy for sickle cell disease is currently in active trials. Collecting hematopoietic progenitor cells safely and effectively is challenging, however, because granulocyte colony stimulating factor, the drug used most commonly for mobilization, can cause life-threatening vaso-occlusion in patients with sickle cell disease, and bone marrow harvest requires general anesthesia and multiple hip bone punctures. Plerixafor is an inhibitor of the CXCR4 chemokine receptor on hematopoietic progenitor cells, blocking its binding to SDF-1 (CXCL12) on bone marrow stroma. In support of a clinical trial in patients with sickle cell disease of plerixafor mobilization (NCT02193191), we administered plerixafor to sickle cell mice and found that it mobilizes hematopoietic progenitor cells without evidence of concomitant cell activation or brain vaso-occlusion.

KW - Endothelial cell activation

KW - Hematopoietic progenitor cell mobilization

KW - Neutrophil activation

KW - Platelet activation

KW - Plerixafor

KW - Sickle cell disease

UR - http://www.scopus.com/inward/record.url?scp=84959186003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959186003&partnerID=8YFLogxK

U2 - 10.1016/j.bcmd.2015.12.008

DO - 10.1016/j.bcmd.2015.12.008

M3 - Article

VL - 57

SP - 67

EP - 70

JO - Blood Cells, Molecules, and Diseases

JF - Blood Cells, Molecules, and Diseases

SN - 1079-9796

ER -